Specialty medical injectable medication program, requirement and policy updates July 2026
Review the following tables to determine changes to our specialty medical injectable medication programs and drug policy updates for July 2026.
Review the following tables to determine changes to our specialty medical injectable medication programs and drug policy updates.
Medical Benefit Therapeutic Equivalent Medications – Excluded Drugs
Effective Oct. 1, 2026, the following specialty injectable medications are being added to Medical Benefit Therapeutic Equivalent Medications – Excluded Drugs for UnitedHealthcare commercial business:
| Excluded Medication | HCPCs Code(s) | Therapeutic Class | Other Options |
| Denosumab products – Prolia® Biosimilars | |||
| Bosaya™ (denosumab-kyqq) |
Q5161 | Osteoporosis | Prolia, Bildyos®, Enoby™, and Stoboclo® |
| Conexxence™ (denosumab-bnht) |
Q5158 | ||
| Ospomyv™ (denosumab-dssb) |
Q5159 | ||
| Exdensur™ (depemokimab-ulaa) |
J2361 | Asthma | Fasenra™ or Nucala® and Tezspire® |
| Qivigy® (immune globulin intravenous, human-kthm) |
J1577 | Immune Globulin | Bivigam®, Cutaquig®, Cuvitru®, Flebogamma® DIF, Gammagard® Liquid, Gammagard™ S/D, Gammaked™, Gammaplex®, Gamunex®-C, Hizentra®, HyQvia®, Octagam®, Privigen®, Xembify® |
| Yimmugo® (immune globulin intravenous, human-dira) |
J1553 | ||
Updates to drug program requirements and drug policies
Effective Oct. 1, 2026, the following drug program requirements and drug policy updates will be made to UnitedHealthcare commercial business:
| Medication Name | HCPC(s) | Summary of Changes |
| Avlayah™ (tividenofusp alfa-eknm) |
J3490/J3590/C9399 |
|
| Bosaya (denosumab-kyqq) Biosimilar to Prolia |
Q5161 |
|
| Conexxence (denosumab-bnht) Biosimilar to Prolia |
Q5158 |
|
| Exdensur (depemokimab-ulaa) |
J2361 |
|
| Kresladi™ (marnetegragene autotemcel) |
J3490/J3590/C9399 |
|
| Loargys® (pegzilarginase-nbln) |
J3490/J3590/C9399 |
|
| Ospomyv (denosumab-dssb) Biosimilar to Prolia |
Q5159 |
|
| Qivigy (immune globulin intravenous, human-kthm) |
J1577 |
|
UnitedHealthcare will honor all approved prior authorizations on file until the end date on the authorization or the date the member’s eligibility changes. Upon prior authorization renewal, the updated policy will apply.
Note: Certain specialty medical injectable programs and updates may not be implemented for some providers or commercial members where prohibited by applicable state insurance mandates or regulations. Providers are encouraged to confirm whether prior authorization or other program requirements apply.
For questions, please contact your broker or UnitedHealthcare representative.
Medication Sourcing for Outpatient Hospital Providers Only
Effective Oct. 1, 2026, the following specialty medical injectable medication is being added to Medication Sourcing for Outpatient Hospital Providers Only for UnitedHealthcare commercial business:
| Medication Name | HCPCS Code(s) |
Specialty Pharmacy |
| Avlayah (tividenofusp alfa-eknm) |
J3490/J3590/C9399 | Orsini Pharmaceutical Services |
| Bosaya (denosumab-kyqq) Biosimilar to Prolia |
Q5161 | TBD |
| Conexxence (denosumab-bnht) Biosimilar to Prolia |
Q5158 |
Amber Specialty Pharmacy |
| Exdensur (depemokimab-ulaa) |
J2361 | Caremark (CVS Specialty) |
| Loargys® (pegzilarginase-nbln) |
J3490/J3590/C9399 |
Orsini Pharmaceutical Services |
| Ospomyv (denosumab-dssb) Biosimilar to Prolia |
Q5159 |
TBD |
| Qivigy (immune globulin intravenous, human-kthm) |
J1577 |
TBD |
Review the UnitedHealthcare Commercial Plan Drugs that Require Sourcing List.
For questions, please contact your broker or UnitedHealthcare representative.